Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0022568 (keratitis)
 5,133 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A 52-year-old woman contracted a serious influenza; three weeks later a dropshaped patch, whitish-yellow in color and deeply vascularized, was seen on the posterior upper surface of the cornea of one eye. It was accompanied by an anterior uveitis. The Tyndall phenomenon was positive. The sensibility of the upper quadrants of the cornea was reduced, temporally to 1.84 g/mm2, nasally to 3.20 g/mm2. Central vision was approx. 0.03. The condition was treated locally with steroid eye drops and generally with Diclofenac 2 X 50 mg. The infiltration became clearer as a result and vision increased to 0.8. Further examinations over a period of 2-1/2 years revealed crystal-like deposits and fiberglass-like structures. The erythrocyte sedimentation rate remained elevated. Since the etiology of these changes is still unknown, the authors suggest the purely descriptive term 'deep parenchymatous keratitis'. It would seem likely that this is a herpetic condition, especially in view of the decreased sensibility of the upper quadrants of the cornea.
 ...
PMID:[Inflammatory and regressive changes of the posterior surface of the cornea]. 672 40

The ocular pharmacokinetics of topical diclofenac sodium was studied in two experimental models of ocular inflammation and compared to physiological conditions. Keratitis or uveitis were induced by intrastromal injection of clove oil or by intravitreal lipopolysaccharide in rabbits. The control eyes were not inflamed. Simultaneously to the induction of inflammation, 30 microl of 0.1% diclofenac were applied topically in the right eye. Diclofenac levels were measured by HPLC in the cornea, aqueous humor (AH), iris/ciliary body (ICB) and plasma 30 min, 1, 3, 6 and 12 h after application. In physiological conditions, diclofenac reached a peak level in the cornea and ICB at 30 min slowly decreasing afterwards. Low levels of diclofenac were found in AH. In keratitic eyes, two peak levels which were significantly higher than in the controls were found in the cornea 30 min and 3 h after application. Diclofenac concentrations in keratitic AH and ICB were lower than in controls. In uveitic eyes, corneal and ICB levels peaked at 30 min, being significantly higher than in controls, and decreased quickly to very low levels at 1 h after application. In uveitic AH, diclofenac levels were lower than in controls. Plasma levels were very low (less than 0.1 microg/ml) in all experimental groups. It is concluded that the ocular pharmacokinetics of topical diclofenac is affected by inflammatory processes in the eye, reaching higher levels in the target tissues.
 ...
PMID:The ocular pharmacokinetics of topical diclofenac is affected by ocular inflammation. 1032 47